Trial Profile

IDL-2965 - A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDL 2965 (Primary)
Indications Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Renal failure
Focus Adverse reactions
Sponsors Indalo Therapeutics

31 Jul 2020 Status changed from recruiting to discontinued.
20 May 2020 Results (n=24) assessing safety and PK results from the healthy volunteers multiple ascending dose cohorts (Part B) compared to therapeutic concentrations in the bleomycin model, presented at the 116th International Conference of the American Thoracic Society.
11 Nov 2019 Results from single- and multiple-ascending dose (SAD and MAD) portions of the study presented in the Indalo Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com